glp-1 receptor agonists and Research to Treat Overeating and Substance Use Disorders Frontiers | GLP-1 receptor agonist
Description
Understanding the differences between tirzepatide tablets and injections provides context on how these delivery innovations are evolving
Subgroup analyses were performed to explore efficacy differences in receptor specificity
PLoS One 9, e103114
2024;63(5):e1001
For most GLP-1 weight management medications, Anthem requires a BMI of 30 or greater (clinical obesity) or a BMI of 27 or greater with at least one weight-related comorbidity
These wider impacts are valuable for those suffering from metabolic issues or obesity-related wellness problems
